Biocon has reported results for first quarter ended June 30, 2013.
The company has reported 25.59% rise in its net profit at Rs 86.46 crore for the quarter as compared to Rs 68.84 crore for the same quarter in the previous year. Total income of the company has increased by 21.20% at Rs 568.78 crore for quarter under review as compared to Rs 469.27 crore for the quarter ended June 30, 2012.
On the consolidated basis, the group registered a rise of 18.65% in its net profit after taxes, minority interest at Rs 93.50 crore for the quarter as compared to Rs 78.80 crore for the same quarter in the previous year. Total income of the company, on consolidated basis, has increased by 22.03% at Rs 723.17 crore for quarter under review as compared to Rs 592.60 crore for the quarter ended June 30, 2012.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.15 |
| Dr. Reddys Labs. | 1350.00 |
| Cipla | 1440.30 |
| Zydus Lifesciences | 1101.50 |
| Lupin | 2342.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: